Please select the eligibility criteria that correspond to the clinical trial below.
Title: Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin"
Brief Summary: A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy, safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin resistance and obesity in overweight, hyperlipidemic patients, both as monotherapy and in combination with Atorvastatin

Total participation for each patient is approximately 16-17 weeks, which may include up to a 2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up. During the run-in period patients taking statins, statin combination or Zetia will undergo a 'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their same diet prior to entering the study). They will be asked to defer initiating any weight loss diets or meaningful changes in their activity level until after they have completed the study. Once randomized into the double blind study, patients will visit the clinic every two weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the double-blind study medication will be discontinued. Patients will attend a follow up visit two weeks after their final dose for safety evaluation.


Options:
A: Inclusion Criteria:

* Patient aged ≥ 20 years old and \< 75 years old.
* Patient who was eligible and able to participate in the study and accepts to enter the study by signing written informed consent.
* Patient with fasting LDL-C \> 100 mg/dL. The concentration of LDL-C is obtained from laboratory examination.
* Patient with at least one of the following description (NCEP ATP III guideline).
* Female patient with child-bearing potential must take reliable contraception method(s) during the participation of the study.

Exclusion Criteria:

* Patient who has participated in other investigational studies within 3 months.
* Patient took medication and natural health foods known to alter blood lipid profiles within 4 weeks.
* Patient is taking any medication or food that is prohibited by the study.
* Patient taking Amiodarone will be excluded from this study (due to long half life of this medication).
* Patient is diagnosed with type 1 DM or has been using insulin/insulin analog medication.
* Patient with a history of multiple drug allergies or with a known allergy to HMG-CoA reductase inhibitors.
* Patient with TG \> 400 mg/dL.
* Excessive obesity defined as BMI above 35 kg/m2.
* Cerebral vascular disease (including cerebrovascular hemorrhage or ischemia, transient ischemic attack) diagnosed within 3 months.
* Myocardial infarction, heart failure (NYHA class III or IV), gross cardiac enlargement (cardiothoracic ratio \> 0.5), significant heart block or cardiac arrhythmias within 3 months; history of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardia, pacemaker or implantable cardiac device were not eligible for this study.
* Patient with advanced renal disorder (Serum creatinine levels ≥ 2 mg/dL and BUN ≥ 25 mg/dL).
* Patient with advanced hepatic disorder (AST or ALT level ≥ 100 IU/L)
* Patient with CK level \> 5 × ULRR at any time point between Visit 1 and Visit 2.
* Patient with poorly controlled diabetes mellitus (HbA1c \> 9.0%) or patient with severe hypertension (\> 180 mmHg for systolic or \> 120 mmHg in diastolic blood pressure).
* Patient with hypothyroidism, hereditary muscular disorders, family history of the above or history of drug-induced myopathy.
* Patient has significant alcohol consumption (\> 65 mL pure alcohol) within 48 hours before Visit 2.
* Any major surgery within 3 months prior to Visit 2.
* Female patient who is lactating, being pregnant or plans to become pregnant.
* Patient with conditions judged by the investigator as unsuitable for the study.
B: Inclusion Criteria:

* Discontinuation of all cholesterol lowing drugs, including dietary supplements.
* Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.

Exclusion Criteria:

* The use of lipid lowering drugs or dietary supplements after Visit 1.
* Active arterial disease eg Unstable angina, or recent arterial surgery
* Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
* Abnormal laboratory parameters as defined in the protocol.
C: Inclusion Criteria:

* Age: 18-75 years
* Female patients must not be pregnant or breast-feeding
* Patients must be moderately overweight
* All patients must have abnormal cholesterol levels or a history of abnormal cholesterol levels as defined by the protocol.
* Patients taking medication to lower their cholesterol must be willing, in some cases, to discontinue their medications during the study Stable weight (a history of increasing or decreasing no more than 6.6 lbs \[3 kg\]) for at least 2 months prior to the study;

Exclusion Criteria

* Cancer or a history of a cancer within 5 years before screening, other than some skin cancers
* Patients planning elective surgery during the study
* Patients with a history of diabetes mellitus at study onset
* History of intolerance to, or adverse effect from atorvastatin
* History of weight loss due to stomach bypass or eating disorder
* All patients may not have had a stroke, TIA, an acute myocardial infarction, angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy) within 5 months of screening
D: Inclusion Criteria:

* \> or = 18 years of age
* Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)
* Able to swallow pill form of drug

Exclusion Criteria:

* \< 18 years of age
* enrollment in another ongoing trial
* paroxysmal atrial fibrillation
* hemodynamic instability
* atrial fibrillation ablation within 6 months of enrollment
* a contraindication for anticoagulation
* severe valvular heart disease
* presence of single lead implantable cardioverter defibrillator
* unstable angina
* New York Heart Association (NYHA) Class IV heart failure
* hyperthyroidism
* uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications
* an illness that would limit life expectancy to less than 1 year
* use of statins within the previous 30 days
* significant coronary artery disease or lipid abnormalities necessitating statin therapy
* implanted devices for active management of arrhythmias by pacing or defibrillation
* lack of access to a telephone
* illicit drug use
* alcohol abuse
* hypersensitivity to atorvastatin by history
* pregnancy
* sexually active female subjects not on contraception or surgically sterilized
* nursing mothers
* chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal \[ULN\] of laboratory reference range)
* severe renal disease (creatinine \> 200 mmol/L)
* inflammatory muscle disease or creatine kinase (CK) \> 3 times ULN
* concurrent treatment with cyclosporine, fibrates, or high-dose niacin

Answer: C